Imaging biomarker

Lunit to Present 5 Abstracts at the ECR Meeting 2022

Retrieved on: 
Monday, July 11, 2022
Radiological Society of North America, Philips, Survival, Partnership, Solution, AGFA, FDA, 2021 Essex County Council election, COVID-19, Congress, Radiology, Risk assessment, Achievement, CEO, INFINITT Healthcare, Breast cancer, ECR, Software, Industry, University, AI, IBM, FUJIFILM, Imaging biomarker, RSNA, ICU, Risk, Multimedia, ECMO, Probability, Patient, Prognosis, European Congress of Radiology, University of Basel, Medical device, Medical imaging, Mammography

SEOUL, South Korea, July 11, 2022 /PRNewswire/ -- Lunit has announced the presentation of five abstracts featuring its AI solutions for chest and breast radiology at the European Congress of Radiology (ECR) Meeting 2022, held in Vienna, Austria, July 13th through 17th.

Key Points: 
  • SEOUL, South Korea, July 11, 2022 /PRNewswire/ -- Lunit has announced the presentation of five abstracts featuring its AI solutions for chest and breast radiology at the European Congress of Radiology (ECR) Meeting 2022, held in Vienna, Austria, July 13th through 17th.
  • Furthermore, a joint study with the University of Basel focuses on Lunit's CE-marked chest x-ray AI solution, Lunit INSIGHT CXR.
  • The findings indicate that radiologists can substantially improve accuracy and productivity with the assistance of Lunit INSIGHT CXR.
  • Visit us at EXPO X1 - AI area - Booth #30 for product demonstrations of Lunit INSIGHT CXR, Lunit INSIGHT MMG, and Lunit INSIGHT DBT.

Lunit to Present 5 Abstracts at the ECR Meeting 2022

Retrieved on: 
Monday, July 11, 2022
Radiological Society of North America, Philips, Survival, Partnership, Solution, AGFA, FDA, 2021 Essex County Council election, COVID-19, Congress, Radiology, Risk assessment, Achievement, CEO, INFINITT Healthcare, Breast cancer, ECR, Software, Industry, University, AI, IBM, FUJIFILM, Imaging biomarker, RSNA, ICU, Risk, ECMO, Probability, Patient, Prognosis, European Congress of Radiology, University of Basel, Medical device, Medical imaging, Mammography

SEOUL, South Korea, July 11, 2022 /PRNewswire/ -- Lunit has announced the presentation of five abstracts featuring its AI solutions for chest and breast radiology at the European Congress of Radiology (ECR) Meeting 2022, held in Vienna, Austria, July 13th through 17th.

Key Points: 
  • SEOUL, South Korea, July 11, 2022 /PRNewswire/ -- Lunit has announced the presentation of five abstracts featuring its AI solutions for chest and breast radiology at the European Congress of Radiology (ECR) Meeting 2022, held in Vienna, Austria, July 13th through 17th.
  • Furthermore, a joint study with the University of Basel focuses on Lunit's CE-marked chest x-ray AI solution, Lunit INSIGHT CXR.
  • The findings indicate that radiologists can substantially improve accuracy and productivity with the assistance of Lunit INSIGHT CXR.
  • Visit us at EXPO X1 - AI area - Booth #30 for product demonstrations of Lunit INSIGHT CXR, Lunit INSIGHT MMG, and Lunit INSIGHT DBT.

Quibim Teams Up With Molecular Imaging Partners And GE Healthcare To Advance Total-Body PET Scanning

Retrieved on: 
Tuesday, July 20, 2021
Medicine, Branches of biology, Clinical medicine, Medical physics, Medical imaging, Biomarkers, Neuroimaging, Antimatter, Positron emission tomography, Molecular imaging, Imaging biomarker, Imaging

PET imaging, a safe medical examination, allows visualization of extremely low amounts of radioactive compounds administered to patients and provides functional information of processes occurring within the body.

Key Points: 
  • PET imaging, a safe medical examination, allows visualization of extremely low amounts of radioactive compounds administered to patients and provides functional information of processes occurring within the body.
  • The High Sensitivity Molecular Imaging project goes a step beyond current PET technology with the goal of developing new applications of PET in biomedical research.
  • Quibim, a company based in Valencia, Madrid and Palo Alto, California (USA), builds whole-body imaging solutions for systems biology problems.
  • A prominent medical imaging analysis provider, Quibim plans to become the global leader in virtual biopsies, using quantitative imaging biomarkers to unlock complex diseases signals in medical images.

Quibim Teams Up With Molecular Imaging Partners And GE Healthcare To Advance Total-Body PET Scanning

Retrieved on: 
Tuesday, July 20, 2021
Medicine, Branches of biology, Clinical medicine, Medical physics, Medical imaging, Biomarkers, Neuroimaging, Antimatter, Positron emission tomography, Molecular imaging, Imaging biomarker, Imaging

PET imaging, a safe medical examination, allows visualization of extremely low amounts of radioactive compounds administered to patients and provides functional information of processes occurring within the body.

Key Points: 
  • PET imaging, a safe medical examination, allows visualization of extremely low amounts of radioactive compounds administered to patients and provides functional information of processes occurring within the body.
  • The High Sensitivity Molecular Imaging project goes a step beyond current PET technology with the goal of developing new applications of PET in biomedical research.
  • Quibim, a company based in Valencia, Madrid and Palo Alto, California (USA), builds whole-body imaging solutions for systems biology problems.
  • A prominent medical imaging analysis provider, Quibim plans to become the global leader in virtual biopsies, using quantitative imaging biomarkers to unlock complex diseases signals in medical images.

Terns Announces Initiation of Patient Dosing in AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201

Retrieved on: 
Thursday, June 24, 2021
Branches of biology, Biomarkers, Medicine, Biology, Clinical research, Biotechnology, Chemical pathology, Imaging biomarker, Placebo, Clinical trial

The primary objective of the AVIATION Trial is to evaluate the safety and tolerability of TERN-201 versus placebo when given for 12 weeks in patients with NASH.

Key Points: 
  • The primary objective of the AVIATION Trial is to evaluate the safety and tolerability of TERN-201 versus placebo when given for 12 weeks in patients with NASH.
  • Each part of the AVIATION Trial is planned to include approximately 20 patients receiving each of the designated doses of TERN-201 and approximately 10 patients receiving placebo.
  • The clinical trial will also explore the effects of TERN-201 on NASH imaging biomarkers (such as cT1) and NASH blood biomarkers (such as CK-18).
  • Preliminary topline 12-week data from Part 1 and Part 2 of the AVIATION Trial are expected in 1H 2022 and 2H 2022, respectively.

First Phase Results of MYLUNG Consortium Provide Historical View of Biomarker Testing Patterns and Identify Data Gaps for Ongoing Prospective Research

Retrieved on: 
Friday, June 4, 2021
Oncology, Health, Other Health, Research, Science, Biotechnology, Biomarkers, Biology, Branches of biology, Medicine, Imaging biomarker, Cancer biomarker, The US Oncology Network, US Oncology Research, Ontada, THE US ONCOLOGY NETWORK, US ONCOLOGY RESEARCH, ONTADA

The findings provide a close-up look at current biomarker testing rates and turnaround times for patients with mNSCLC treated in community practices within The Network.

Key Points: 
  • The findings provide a close-up look at current biomarker testing rates and turnaround times for patients with mNSCLC treated in community practices within The Network.
  • Unfortunately, barriers exist that prevent the necessary comprehensive biomarker testing that enables the use of these treatments.
  • The MYLUNG Consortium is a collaborative and innovative research study comprised of three protocols over a five-year period.
  • Ontada is an oncology data, research and technology business dedicated to improving the lives of cancer patients.

As ASCO 2021 Spotlights Biomarkers, New InCrowd Data Shows 80% of US Oncologists Anticipate Broader Liquid Biomarkers Use, Despite Insurance Barriers

Retrieved on: 
Wednesday, June 2, 2021
Oncology, Health, Other Health, General Health, Pharmaceutical, Biotechnology, Biomarkers, Branches of biology, Biology, Life sciences, Oncology, Imaging biomarker

Data are from the Oncology Biomarker Testing report from InCrowd , the pioneer for real-time, high-quality primary market intelligence for the life science industry.

Key Points: 
  • Data are from the Oncology Biomarker Testing report from InCrowd , the pioneer for real-time, high-quality primary market intelligence for the life science industry.
  • Despite insurance reimbursement barriers and limited indications, physicians see the potential for helping patients to get faster results with less invasive liquid testing for certain tumor types.
  • At present 93% of oncologists in the report order initial biomarker tests upon diagnosis, and 61% order non-standard biomarker tests after first-line treatment failure.
  • Data in the Oncology Biomarkers Testing report were sourced April 15-21, 2021 from InCrowds proprietary panel of healthcare professionals.

Clinical and Imaging Biomarkers in Parkinsonian Syndromes, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, April 26, 2021
Branches of biology, Biology, Biomarkers, Medicine, Geriatrics, Aging-associated diseases, Psychiatric diagnosis, Parkinson's disease, Imaging biomarker, Parkinsonism

b"TORONTO, April 26, 2021 /PRNewswire-PRWeb/ -- This webinar will look at clinical and imaging biomarkers in Parkinsonian syndromes to provide trial sponsors a rounded overview of key challenges and considerations.\nThis webinar aims to give a clinical overview of the presentation of Parkinsonian syndromes including the important clinical features that aid correct diagnosis.

Key Points: 
  • b"TORONTO, April 26, 2021 /PRNewswire-PRWeb/ -- This webinar will look at clinical and imaging biomarkers in Parkinsonian syndromes to provide trial sponsors a rounded overview of key challenges and considerations.\nThis webinar aims to give a clinical overview of the presentation of Parkinsonian syndromes including the important clinical features that aid correct diagnosis.
  • It will also address the diagnostic challenges faced when recruiting for clinical trials and when the use of imaging, in particular MRI, can be useful in differential diagnosis of Parkinsonism.\nThe second part of the webinar will review the role of traditional imaging biomarkers in Parkinson's disease clinical trials.
  • For example, the use of dopamine transporter (DAT) neuroimaging, which remains a useful technique at the early stages of clinical trials.\nThe webinar will also highlight the use of neuroimaging biomarkers to measure disease progression in Parkinson's disease.
  • Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.\nAyesha Rashid, Xtalks, +1 (416) 977-6555 x 272, [email protected]\n"

LUNGevity Launches Campaign Focused on Increasing Lung Cancer Survival by Driving Awareness of Comprehensive Biomarker Testing

Retrieved on: 
Tuesday, April 20, 2021
Biomarkers, Branches of biology, Biology, Life sciences, Cancer, Lung cancer, Imaging biomarker, Cancer biomarker

"Every lung cancer patient has a right to be informed about comprehensive biomarker testing and to have a discussion with their healthcare team about a personalized treatment plan based on the results.

Key Points: 
  • "Every lung cancer patient has a right to be informed about comprehensive biomarker testing and to have a discussion with their healthcare team about a personalized treatment plan based on the results.
  • No One Missed will help make certain that every person diagnosed with non-small cell lung cancer has a chance to pursue the best care.
  • "\nThe campaign will encourage people diagnosed with non-small cell lung cancer to follow three steps for biomarker testing: Talk, Test, and Treat.\nTalkto your healthcare team about comprehensive biomarker testing.
  • "\nThe campaign website provides resources to patients and their caregivers to support their biomarker testing process.

The Potential of Advanced Imaging to Show the Early Treatment Effects of Berubicin in Brain Cancer, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, March 30, 2021
Branches of biology, Biology, Biomarkers, Medicine, Imaging biomarker, Oncology, Alzheimer's Disease Neuroimaging Initiative

Pseudo-progression is difficult to distinguish from disease progression using routine clinical radiographic assessments.

Key Points: 
  • Pseudo-progression is difficult to distinguish from disease progression using routine clinical radiographic assessments.
  • Novel imaging strategies and artificial intelligence ('AI') driven imaging biomarkers can advance neuro-oncology clinical trials by providing deep analysis of disease progression and treatment response.
  • For more information, or to register for this event, visit The Potential of Advanced Imaging to Show the Early Treatment Effects of Berubicin in Brain Cancer.
  • Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community.